Fig 5 - by Maha Rehman (17114332)

Knock-down of Atox1 in SW620 cells decreased cell migration and colony formation. by Arundhati Jana (157555)

IFN-β signalling pathway stimulation by Poly(I:C) decreased 5’terminally deleted CVB3 RNA forms viral loads, cardiac lesions and mortality in DBA/2J mice. by Domitille Callon (17723936)

Transcriptomic analysis of the long-lived and short-lived Atg1 over-expressing flies reveals decreased lipid metabolism. by Ivana Bjedov (75652)

Activation of vMC-dDG pathway decreases the competitive advantage of fear engram cells in the dDG neuronal network and attenuates fear generalization. by Kun Cui (2070772)

<i>Furin</i> mutant hearts show a decreased in the number of phospo-Smad positive cells at the AV junction. by Laurent Dupays (2940330)

Fig 5 - by Felix Bosch (10024550)

Klf5 and eIF5a suppress Ang II–induced expression of NOX1 in VSMCs. by Dong Ma (584680)

Subjects:

Fig 5 - by Marian Adan (16641634)

Subjects:

Decreased reductase activity and increased round body formation in the <i>gpsA</i> mutant. by Dan Drecktrah (36180)

Additional behavioral patterns in the 5€, 100€, and 1000€ treatments. by Pablo Brañas-Garza (336425)

Search duration decreases with target value and increases with the environment’s probability of containing a reward target. by Michael R. Traner (11836571)

Fig 5 - by Jie He (132999)

Decreased respiratory performance of children and adolescents with myelomeningocele who use a wheelchair – preliminary data by E.J. Martins (7141313)

MYCN overexpression leads to decreased <i>id2a</i> expression in early SCG. by Rodrigo Ibarra-García-Padilla (19697623)

m⁵C modified sites C131 and C2017 positively regulate HBV replication. by Jiangpeng Feng (9287738)

Subjects:

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects: